TY - JOUR KW - Adult KW - Buprenorphine/adverse effects KW - Case-Control Studies KW - Depression/chemically induced/complications KW - Female KW - Humans KW - Male KW - Primary Health Care KW - Sex Factors KW - Sleep Initiation and Maintenance Disorders/chemically induced/complications KW - Young Adult KW - buprenorphine KW - Depression KW - primary care KW - Sleep AU - Sarah L. Garnaat AU - Risa B. Weisberg AU - Lisa A. Uebelacker AU - Debra S. Herman AU - Genie L. Bailey AU - Bradley J. Anderson AU - Katherine M. Sharkey AU - Michael D. Stein A1 - AB - BACKGROUND: Sleep disturbance is common among patients receiving long-term opioid therapies, such as methadone maintenance. However, little is known about sleep disturbances in patients receiving medication treatment with buprenorphine. We sought to determine the frequency of subjective sleep disturbance in a sample of patients receiving medication treatment and to examine clinical factors related to sleep disturbance. METHODS: Participants were 328 persons receiving buprenorphine at 3 primary care sites. Sleep difficulty was assessed 2 questions adapted from the Patient Health Questionnaire-9 (PHQ-9) item assessing sleep. Depressive symptoms were assessed using the Center for Epidemiologic Studies Depression Scale (CESD)-10 and PHQ-2. In addition, information was gathered on participant demographics and treatment characteristics. Demographics, buprenorphine treatment history, and depressive symptoms were compared for those with and without self-reported sleep difficulty. Logistic regression was used to estimate the adjusted association of sleep disturbance with these correlates. RESULTS: Seventy-one percent of persons receiving medication treatment with buprenorphine in the present study reported sleep difficulty. Persons reporting sleep disturbance reported shorter time in buprenorphine treatment and more depressed mood compared with those without sleep difficulty (p < .01). Men were significantly less likely to report disturbed sleep than women (odds ratio [OR] = 0.57, 95% confidence interval [CI]: 0.33, 0.98). Sleep disturbance was not associated significantly with age, ethnicity, educational attainment, or buprenorphine dose. CONCLUSIONS: Sleep disturbance is common in patients receiving medication treatment with buprenorphine and is associated with more depressive symptoms as well as a shorter duration of medication treatment. Future research, using subjective and objective sleep measures, is warranted to understand whether sleep disturbance is mitigated by longer buprenorphine treatment and whether difficulty sleeping predicts buprenorphine discontinuation among patients seeking treatment for opioid dependence. AD - a Butler Hospital , Providence , Rhode Island , USA.; b Alpert Medical School of Brown University , Department of Psychiatry and Human Behavior , Providence , Rhode Island , USA.; b Alpert Medical School of Brown University , Department of Psychiatry and Human Behavior , Providence , Rhode Island , USA.; c VA Boston Healthcare System , Boston , Massachusetts , USA.; d Boston University School of Medicine , Department of Psychiatry , Boston , Massachusetts , USA.; a Butler Hospital , Providence , Rhode Island , USA.; b Alpert Medical School of Brown University , Department of Psychiatry and Human Behavior , Providence , Rhode Island , USA.; a Butler Hospital , Providence , Rhode Island , USA.; b Alpert Medical School of Brown University , Department of Psychiatry and Human Behavior , Providence , Rhode Island , USA.; b Alpert Medical School of Brown University , Department of Psychiatry and Human Behavior , Providence , Rhode Island , USA.; e Stanley Street Treatment and Resources , Fall River , Massachusetts , USA.; a Butler Hospital , Providence , Rhode Island , USA.; b Alpert Medical School of Brown University , Department of Psychiatry and Human Behavior , Providence , Rhode Island , USA.; f Rhode Island Hospital , Providence , Rhode Island , USA.; g Alpert Medical School of Brown University , Department of Medicine , Providence , Rhode Island , USA.; a Butler Hospital , Providence , Rhode Island , USA.; g Alpert Medical School of Brown University , Department of Medicine , Providence , Rhode Island , USA. BT - Substance abuse C5 - Healthcare Disparities; Measures; Opioids & Substance Use CP - 4 CY - United States DO - 10.1080/08897077.2017.1361498 IS - 4 JF - Substance abuse LA - eng M1 - Journal Article N2 - BACKGROUND: Sleep disturbance is common among patients receiving long-term opioid therapies, such as methadone maintenance. However, little is known about sleep disturbances in patients receiving medication treatment with buprenorphine. We sought to determine the frequency of subjective sleep disturbance in a sample of patients receiving medication treatment and to examine clinical factors related to sleep disturbance. METHODS: Participants were 328 persons receiving buprenorphine at 3 primary care sites. Sleep difficulty was assessed 2 questions adapted from the Patient Health Questionnaire-9 (PHQ-9) item assessing sleep. Depressive symptoms were assessed using the Center for Epidemiologic Studies Depression Scale (CESD)-10 and PHQ-2. In addition, information was gathered on participant demographics and treatment characteristics. Demographics, buprenorphine treatment history, and depressive symptoms were compared for those with and without self-reported sleep difficulty. Logistic regression was used to estimate the adjusted association of sleep disturbance with these correlates. RESULTS: Seventy-one percent of persons receiving medication treatment with buprenorphine in the present study reported sleep difficulty. Persons reporting sleep disturbance reported shorter time in buprenorphine treatment and more depressed mood compared with those without sleep difficulty (p < .01). Men were significantly less likely to report disturbed sleep than women (odds ratio [OR] = 0.57, 95% confidence interval [CI]: 0.33, 0.98). Sleep disturbance was not associated significantly with age, ethnicity, educational attainment, or buprenorphine dose. CONCLUSIONS: Sleep disturbance is common in patients receiving medication treatment with buprenorphine and is associated with more depressive symptoms as well as a shorter duration of medication treatment. Future research, using subjective and objective sleep measures, is warranted to understand whether sleep disturbance is mitigated by longer buprenorphine treatment and whether difficulty sleeping predicts buprenorphine discontinuation among patients seeking treatment for opioid dependence. PP - United States PY - 2017 SN - 1547-0164; 0889-7077 SP - 450 EP - 454 EP - T1 - The overlap of sleep disturbance and depression in primary care patients treated with buprenorphine T2 - Substance abuse TI - The overlap of sleep disturbance and depression in primary care patients treated with buprenorphine U1 - Healthcare Disparities; Measures; Opioids & Substance Use U2 - 28901836 U3 - 10.1080/08897077.2017.1361498 VL - 38 VO - 1547-0164; 0889-7077 Y1 - 2017 Y2 - Oct-Dec ER -